French Study on Using Blood Tests to Detect Residual Cancer After Surgery in Patients With Colorectal Cancer That Has Spread to the Liver

What this Trial Is About

Researchers are investigating new ways to improve personalized treatment for colorectal cancer patients with liver metastases by using circulating tumor DNA ctDNA tests. These tests detect cancer traces in blood samples and may help decide who needs additional treatment after surgery. The GUIDE.MRD consortium, including the French FRENCH.MRD.CRLM study, aims to establish reliable ctDNA tests and collect data to guide treatment choices more accurately than current methods. The study focuses on patients with colorectal cancer that has spread to the liver and who are treated with surgery or ablation with curative intent. It is an observational study collecting blood samples to analyze ctDNA at various points after surgery, post-chemotherapy, and during follow-up. The researchers will compare several commercial ctDNA tests to find the best ones for clinical use without affecting patient treatment decisions. Participants will provide blood samples at specific times alongside standard care visits, including CT scans, to monitor cancer recurrence and treatment response. The study will assess how well ctDNA results predict disease-free survival, relapse timing, and correlation with imaging results over three years. Participants usual medical care continues while their samples are analyzed for research purposes.

French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM)